The inhibitory effects of bryostatin 1 administration on the growth of rabbit papillomas

Cancer Letters

Volumn 136, Issue 1, 1999, Pages 67-74

  Bodily, Jason M ^a   Hoopes, David J ^a   Roeder, Beverly L ^a   Gilbert, Sharon G ^a   Pettit, George R ^b   Herald, Cherry L ^b   Rollins, Darin N ^a   Robison, Richard A ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Bryostatin 1; Cancer therapeutics; Cervical cancer; Papillomavirus; PKC

Indexed keywords

BRYOSTATIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; RABBIT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHETERS, INDWELLING; COTTONTAIL RABBIT PAPILLOMAVIRUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRALESIONAL; LACTONES; MACROLIDES; PAPILLOMA; RABBITS;

COTTONTAIL RABBIT PAPILLOMAVIRUS; ORYCTOLAGUS CUNICULUS; PAPILLOMAVIRUS;

EID: 0032996679     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00310-3     Document Type: Article

References (38)

1. G.R. Pettit, The Bryostatins, in: W. Herz, G.W. Kirby, W. Steglick, C. Tamm (Eds.), Progress in the Chemistry of Organic Natural Products, Vol. 57, Springer, Vienna, 1991, pp. 154-195.
2. Hale K.J., Lennon J.A., Manaviazar S., Javaid M.H., Hobbs C.J. Asymmetric synthesis of the C(17)-C(27) segment of the antineoplastic macrolide bryostatin 1. Tetrahedron Lett. 36:1995;1359-1362.
3. Beijnen J.H., Flora K.P., Halbert G.W., Henrar R.E.C., Slack J.A. CRC/ EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs. Br. J. Cancer. 72:1995;210-218.
4. Dale I.L., Gescher A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int. J. Cancer. 43:1989;158-163.
5. Hornung R.L., Pearson J.W., Beckwith M., Longo D.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines in vitro versus in vivo activity. Cancer Res. 52:1992;101-107.
6. Asiedu C., Biggs J., Lilly M., Kraft A.S. Inhibition of leukemic cell growth by the protein kinase C activator Bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 55:1995;3716-3720.
7. Stone R.M., Sariban E., Pettit G.R., Kufe D.W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 72:1988;208-213.
8. Steube K.G., Drexler H.G. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin 1. Leuk-Lymphoma. 9:1993;141-148.
9. Kraft A.S., William F., Pettit G.R., Lilly M.B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 49:1989;1287-1293.
10. al-Katib A., Mohammad R.M., Dan M., Hussein M.E., Akhtar A., Pettit G.R., Sensenbrenner L.L. Bryostatin 1 induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. 21:1993;61-65.
11. Pettit G.R., Kamano Y., Herald C.L., Tozawa M. Structure of bryostatin 4, an important antineoplastic constituent of geographically diverse Buluga neritina (bryozoa). J. Am. Chem. Soc. 106:1984;6768-6771.
12. Pettit G.R., Herald C.L., Doubek D.L., Herald D.L. Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104:1982;6846-6848.
13. Schuchter L.M., Esa A.H., May W.S., Laulis M.K., Pettit G.R., Hess A.D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res. 51:1991;682-687.
14. Mohammad R.M., Al-Katib A., Pettit G.R., Sensenbrenner L.L. Successful treatment of human Waldenström's macroglobulinemia with combinational biological and chemotherapy agents. Cancer Res. 54:1994;165-168.
15. Basu A., Lazo J.S. Sensitization of human cervical carcinoma cells to cis diamminedichloroplatinum-II by bryostatin 1. Cancer Res. 52:1992;3119-3124.
16. Philip P.A., Rea D., Thavasu P., Carmichael J., Stuart N.S.A., Rockett H., Talbot D.C., Ganesan T., Pettit G.R., Balkwill F., Harris A.L. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. J. Natl. Cancer Inst. 85:1993;1812-1818.
17. Prendiville J., Crowther D., Thatcher N., Woll P.J., Fox B.W., McGown A., Testa N., Stern P., McDermott R., Pettit G.R. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer. 68:1993;418-424.
18. Jayson G.C., Crowther D., Prendiville J., McGown A.T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S., Pettit G.R. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer. 72:1995;461-468.
19. zur Hausen H., Gissmann L., Schlehofer J.R. Viruses in the etiology of human genital cancer. Prog. Med. Virol. 30:1984;170-186.
20. Sebbelov A.M., Kjorstad K.E., Abeler V.M., Norrild B. The prevalence of human papillomavirus type 16 and 18 DNA in cervical cancer in different age groups: a study of incidental cases of cervical cancer in Norway in 1983. Gynecol.-Oncol. 41:1991;141-148.
21. Cervical Cancer. 14:1996;NIH Consensus Statement. pp. 1-38.
22. Beutner K.R., Ferenczy A. Therapeutic approaches to genital cancer. Am. J. Med. 102:1997;28-37.
23. Kreider J.W., Bartlett G.L. The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression. Adv. Cancer Res. 35:1981;81-110.
24. Cattaneo R., Schmid A., Billeter M.A., Sheppard R.D., Udem S.A. Multiple viral mutations rather than host factor cause defective measles virus gene expression in a subacute sclerosing panencephalitis cell line. J. Virol. 62:1988;1388-1397.
25. Brandsma J.L., Yang Z., Barthold S.W., Johnson E.A. Use of a rapid, efficient inoculation method to induce papillomas by cottontail rabbit papillomavirus DNA shows that the E7 gene is required. Proc. Natl. Acad. Sci. USA. 88:1991;4816-4820.
26. Perry-Clark L.M., Meunier L.D. Vascular access ports for chronic serial infusion and blood sampling in New Zealand white rabbits. Lab. Anim. Sci. 41:1991;495-497.
27. McCrady C.W., Staniswalis J., Pettit G.W., Howe C., Grant S. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte macrophage progenitors to recombinant GM-CSF. Br. J. Hematol. 77:1991;5-15.
28. Berkow R.L., Kraft A.S. Bryostatin activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor a non-phorbol macrocyclic lactone. Biochem. Biophys. Res. Commun. 131:1985;1109-1116.
29. Sredni B., Kalechman Y., Albeck M., Gross O., Aurbach D., Sharon P., Sehgal S.N., Gurwith M.J., Michlin H. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin. Immunology. 70:1990;473-477.
30. Taylor L.S., Cox G.W., Melillo G., Bosco M.C., Espinoza-Delgado I. Bryostatin-1 and IFN-γ synergise for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages. Cancer Res. 57:1997;2468-2473.
31. Hall H., Teuscher C., Urie P., Boden B., Robison R. Induced regression of bovine papillomas by intralesional immunotherapy. Ther. Immunol. 1:1994;319-324.
32. Lichtenstein A.K., Berek J., Kahle J., Zigelboim J. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice. Cancer Res. 44:1984;5118-5123.
33. Szallasi Z., Denning M.F., Smith C.B., Dlugosz A.A., Yuspa S.H., Pettit G.W., Blumberg P.M. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol. Pharmacol. 46:1994;840-850.
34. Blumberg P.M., Acs G., Areces L.B., Kazaniez M.G., Lewin N.E., Szallasi Z. Protein kinase C in signal transduction and carcinogenesis. Prog. Clin. Biol. Res. 387:1994;3-19.
35. Jones K.T., Sharpe G.R. Proliferating cell nuclear antigen decreases in normal human keratinocytes with differentiation stimuli but not in an HPV immortalized cell line. Acta. Derm. Venereol. 74:1994;241-244.
36. Armstrong D.J., Roman A. Human papillomavirus type E6 protein is a substrate in vitro of protein kinase C. Biochem. J. 312:1995;667-670.
37. Hummel M., Lim H.B., Laimins L.A. Human papillomavirus type 31b late gene expression is regulated through protein kinase C-mediated changes in RNA processing. J. Virol. 69:1995;3381-3388.
38. Tsao Y.P., Huang C.H., Lin Y.K., Chen S.L. Protein kinase C- and ras-dependent activation of c-jun gene by human papillomavirus type 11 E5a oncoprotein. Cancer Lett. 95:1995;201-205.